Attached files

file filename
EX-99.1 - PRESS RELEASE - AUXILIUM PHARMACEUTICALS INCdex991.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 20, 2011

 

 

Auxilium Pharmaceuticals, Inc.

(Exact Name of Registrant Specified in Charter)

 

 

 

Delaware   000-50855   23-3016883

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

40 Valley Stream Parkway

Malvern, PA

 

19355

(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (484) 321-5900

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 7.01 Regulation FD Disclosure.

On May 20, 2011, Auxilium Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company received a $7.5 million regulatory milestone from Pfizer, Inc. (“Pfizer”) following the first sale of XIAPEX® in Germany, a major EU market and that XIAPEX is now available for sale in the United Kingdom, Germany, Denmark, Sweden, Finland, Norway and Austria. XIAPEX is a new non-surgical treatment option for Dupuytren’s contracture in adult patients with a palpable cord and is the first injectable treatment to be approved in the EU for the treatment of Dupuytren's contracture. Prices for XIAPEX have been published in Austria, Denmark, Norway and the United Kingdom and are in the range of U.S.$1,000 to U.S.$1,400 per vial at current exchange rates. The full text of such press release is furnished as Exhibit 99.1 to this Report.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 7.01 and shall not be deemed to be “filed”:

 

99.1 Press release dated May 20, 2011 issued by the Company

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AUXILIUM PHARMACEUTICALS, INC.
Date: May 20, 2011     By:  

/s/ James E. Fickenscher

      James E. Fickenscher
      Chief Financial Officer


EXHIBIT INDEX

 

Exhibit No.    Description of Exhibit
99.1    Press release dated May 20, 2011 issued by the Company